Nexstim announced today that its pilot study on severe depression most likely will be delayed into Q1 2021 instead of Q4 2020 due to the corona pandemic. While potentially interesting, the study is not part of our valuation and we consider the delay a minor issue. We reiterate our base case of 0.6 SEK.